MedTrace Logo

Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

NCT04049851 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-02-24

No results posted yet for this study

Summary

This study aims at evaluating the safety and efficacy of Moxidectin 2 mg in patients with low intensities of microfilariae of Loa loa.

Conditions

  • Onchocerciasis, Ocular
  • Loiasis

Interventions

DRUG

Moxidectin 2 MG Oral Tablet

One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.

DRUG

Ivermectin 3Mg Tab

3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.

DRUG

Placebo oral tablet

Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.

Sponsors & Collaborators

  • Center for Research on Filariasis and Other Tropical Diseases, Cameroon

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-07
Primary Completion
2023-07-22
Completion
2023-07-22

Countries

  • Cameroon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04049851 on ClinicalTrials.gov